Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression

Psychiatry Research

Volumn 198, Issue 3, 2012, Pages 424-429

  Kurose, Kouichi ^a   Hiratsuka, Kazuyuki ^b   Ishiwata, Kazuya ^a,b   Nishikawa, Jun ^a   Nonen, Shinpei ^c   Azuma, Junichi ^c,d   Kato, Masaki ^e   Wakeno, Masataka ^e   Okugawa, Gaku ^e   Kinoshita, Toshihiko ^e   Kurosawa, Toru ^b   Hasegawa, Ryuichi ^a   Saito, Yoshiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b MEIJI SEIKA KAISHA LTD   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adverse drug reaction; Antidepressant; GWAS; Norepinephrine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

FLUVOXAMINE; MILNACIPRAN; PAROXETINE;

ADULT; ARTICLE; CHROMOSOME 14Q; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE CLUSTER; GENE MAPPING; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; INTRON; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GPI-LINKED PROTEINS; HUMANS; MALE; MIDDLE AGED; NEURAL CELL ADHESION MOLECULES; PAROXETINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84868651038     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.01.023     Document Type: Article

References (25)

1. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
2. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 1995, 57:289-300.
3. Bishop J.R., Moline J., Ellingrod V.L., Schultz S.K., Clayton A.H. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006, 31:2281-2288.
4. Bucan M., Abrahams B.S., Wang K., Glessner J.T., Herman E.I., Sonnenblick L.I., Alvarez Retuerto A.I., Imielinski M., Hadley D., Bradfield J.P., Kim C., Gidaya N.B., Lindquist I., Hutman T., Sigman M., Kustanovich V., Lajonchere C.M., Singleton A., Kim J., Wassink T.H., McMahon W.M., Owley T., Sweeney J.A., Coon H., Nurnberger J.I., Li M., Cantor R.M., Minshew N.J., Sutcliffe J.S., Cook E.H., Dawson G., Buxbaum J.D., Grant S.F., Schellenberg G.D., Geschwind D.H., Hakonarson H. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genetics 2009, 5:e1000536.
5. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Floratos A., Daly M.J., Goldstein D.B., John S., Nelson M.R., Graham J., Park B.K., Dillon J.F., Bernal W., Cordell H.J., Pirmohamed M., Aithal G.P., Day C.P. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 2009, 41:816-819.
6. Devlin B., Roeder K. Genomic control for association studies. Biometrics 1999, 55:997-1004.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition 1995, (SCID-I/P, version 2.0), Biometrics Research, New York State Psychiatric Institute, New York.
8. Heck A., Pfister H., Czamara D., Muller-Myhsok B., Putz B., Lucae S., Hennings J., Ising M. Evidence for associations between MDGA2 polymorphisms and harm avoidance - replication and extension of a genome-wide association finding. Psychiatric Genetics 2011, 21:257-260.
9. Hellquist A., Zucchelli M., Lindgren C.M., Saarialho-Kere U., Jarvinen T.M., Koskenmies S., Julkunen H., Onkamo P., Skoog T., Panelius J., Raisanen-Sokolowski A., Hasan T., Widen E., Gunnarson I., Svenungsson E., Padyukov L., Assadi G., Berglind L., Makela V.V., Kivinen K., Wong A., Cunningham Graham D.S., Vyse T.J., D'Amato M., Kere J. Identification of MAMDC1 as a candidate susceptibility gene for systemic lupus erythematosus (SLE). PLoS One 2009, 4:e8037.
10. Ising M., Lucae S., Binder E.B., Bettecken T., Uhr M., Ripke S., Kohli M.A., Hennings J.M., Horstmann S., Kloiber S., Menke A., Bondy B., Rupprecht R., Domschke K., Baune B.T., Arolt V., Rush A.J., Holsboer F., Muller-Myhsok B. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of General Psychiatry 2009, 66:966-975.
11. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2010, 15:473-500.
12. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., Yamashita M., Takekita Y., Nobuhara K., Azuma J., Kinoshita T. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
13. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., Hosoi Y., Takekita Y., Mandelli L., Azuma J., Kinoshita T. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:398-404.
14. Kato M., Fukuda T., Wakeno M., Okugawa G., Takekita Y., Watanabe S., Yamashita M., Hosoi Y., Azuma J., Kinoshita T., Serretti A. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2009, 150B:115-123.
15. Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F., Gut I., Lathrop M., Collins R. SLCO1B1 variants and statin-induced myopathy-a genomewide study. New England Journal of Medicine 2008, 359:789-799.
16. Litwack E.D., Babey R., Buser R., Gesemann M., O'Leary D.D. Identification and characterization of two novel brain-derived immunoglobulin superfamily members with a unique structural organization. Molecular and Cellular Neurosciences 2004, 25:263-274.
17. Malhotra A.K., Murphy G.M., Kennedy J.L. Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 2004, 161:780-796.
18. Ozeki T., Mushiroda T., Yowang A., Takahashi A., Kubo M., Shirakata Y., Ikezawa Z., Iijima M., Shiohara T., Hashimoto K., Kamatani N., Nakamura Y. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Human Molecular Genetics 2011, 20:1034-1041.
19. Perlis R.H., Laje G., Smoller J.W., Fava M., Rush A.J., McMahon F.J. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009, 34:1819-1828.
20. Rabbee N., Speed T.P. A genotype calling algorithm for affymetrix SNP arrays. Bioinformatics 2006, 22:7-12.
21. Serretti A., Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. The Pharmacogenomics Journal 2004, 4:233-244.
22. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 2007, 12:247-257.
23. Thomas K.L., Ellingrod V.L. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009, 29:822-831.
24. van den Oord E.J., Kuo P.H., Hartmann A.M., Webb B.T., Moller H.J., Hettema J.M., Giegling I., Bukszar J., Rujescu D. Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Archives of General Psychiatry 2008, 65:1062-1071.
25. Wakeno M., Kato M., Okugawa G., Fukuda T., Hosoi Y., Takekita Y., Yamashita M., Nonen S., Azuma J., Kinoshita T. The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Journal of Clinical Psychopharmacology 2008, 28:518-524.